Statins are associated with reduced mortality in multiple myeloma

Kristen Marie Sanfilippo, Jesse Keller, Brian F. Gage, Suhong Luo, Tzu Fei Wang, Gerald Moskowitz, Jason Gumbel, Brandon Blue, Katiuscia O'Brian, Kenneth R. Carson

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Purpose: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen-containing bisphosphonates, which are associated with improved survival in multiple myeloma (MM). To understand the benefit of statins in MM, we evaluated the association between statin use and mortality in a large cohort of patients with MM. Patients and Methods: From the Veterans Administration Central Cancer Registry, we identified patients diagnosed with MM between 1999 and 2013. We defined statin use as the presence of any prescription for a statin within 3 months before or any time after MM diagnosis. Cox proportional hazards regression assessed the association of statin use with mortality, while controlling for known MM prognostic factors. Results: We identified a cohort of 4,957 patients, of whom 2,294 received statin therapy. Statin use was associated with a 21% decrease in all-cause mortality (adjusted hazard ratio, 0.79; 95% CI, 0.73 to 0.86; P < .001) as well as a 24% decrease in MM-specific mortality (adjusted hazard ratio, 0.76; 95% CI, 0.67 to 0.86; P < .001). This association remained significant across all sensitivity analyses. In addition to reductions in mortality, statin use was associated with a 31% decreased risk of developing a skeletal-related event. Conclusion: In this cohort study of US veterans with MM, statin therapy was associated with a reduced risk of both all-cause and MM-specific mortality. Our findings suggest a potential role for statin therapy in patients with MM. The putative benefit of statin therapy in MM should be corroborated in prospective studies.

Original languageEnglish
Pages (from-to)4008-4014
Number of pages7
JournalJournal of Clinical Oncology
Volume34
Issue number33
DOIs
StatePublished - Nov 20 2016

Fingerprint Dive into the research topics of 'Statins are associated with reduced mortality in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Sanfilippo, K. M., Keller, J., Gage, B. F., Luo, S., Wang, T. F., Moskowitz, G., Gumbel, J., Blue, B., O'Brian, K., & Carson, K. R. (2016). Statins are associated with reduced mortality in multiple myeloma. Journal of Clinical Oncology, 34(33), 4008-4014. https://doi.org/10.1200/JCO.2016.68.3482